Stomach slowdown may delay heart attack drug action
NCT ID NCT02251249
First seen May 21, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This completed study looked at whether stomach emptying is slower during a heart attack, which could delay the absorption of crucial antiplatelet drugs. Researchers measured paracetamol levels in the blood every 15 minutes in 23 participants to track stomach emptying. The goal was to understand why some patients don't respond quickly to treatment, potentially leading to better care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMPAIRMENT OF GASTRIC EMPTYING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Bordeaux - Hôpital du Haut Lévèque
Pessac, 33604, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
paracetamol, prasugrel, ticagrelor
What this could lead to
If successful, this could help doctors understand why some heart attack patients don't respond quickly to antiplatelet drugs, potentially leading to better treatment strategies.
What could go wrong
This is a small, early-phase study with only 23 participants, so results may not apply to all patients. It is observational in nature and does not test a new treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.